Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proto-Oncogene Proteins p21(ras) | 15 | 2024 | 1741 | 3.130 |
Why?
|
Proto-Oncogene Proteins B-raf | 18 | 2023 | 2052 | 2.710 |
Why?
|
Colorectal Neoplasms | 29 | 2024 | 6894 | 2.550 |
Why?
|
Drug Resistance, Neoplasm | 23 | 2024 | 5292 | 2.390 |
Why?
|
MAP Kinase Kinase 1 | 5 | 2020 | 331 | 2.190 |
Why?
|
Protein Kinase Inhibitors | 23 | 2024 | 5662 | 1.970 |
Why?
|
MAP Kinase Signaling System | 9 | 2019 | 1485 | 1.810 |
Why?
|
Gastrointestinal Neoplasms | 7 | 2023 | 952 | 1.630 |
Why?
|
Pyrimidinones | 6 | 2024 | 384 | 1.420 |
Why?
|
Mutation | 37 | 2024 | 30025 | 1.380 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 7 | 2023 | 641 | 1.240 |
Why?
|
bcl-X Protein | 3 | 2024 | 410 | 1.210 |
Why?
|
Pyridones | 6 | 2024 | 807 | 1.160 |
Why?
|
raf Kinases | 2 | 2019 | 118 | 1.010 |
Why?
|
Aniline Compounds | 3 | 2024 | 1069 | 0.990 |
Why?
|
DNA, Neoplasm | 7 | 2019 | 1745 | 0.990 |
Why?
|
Sulfonamides | 5 | 2024 | 1973 | 0.980 |
Why?
|
Gene Amplification | 6 | 2020 | 1086 | 0.900 |
Why?
|
Neoplasms | 17 | 2024 | 22083 | 0.890 |
Why?
|
Antineoplastic Agents | 14 | 2024 | 13616 | 0.880 |
Why?
|
Pyridines | 3 | 2024 | 2868 | 0.800 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11729 | 0.780 |
Why?
|
Acetonitriles | 1 | 2021 | 54 | 0.750 |
Why?
|
ras Proteins | 7 | 2019 | 1052 | 0.730 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1008 | 0.710 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 5 | 2024 | 214 | 0.710 |
Why?
|
Pyrimidines | 6 | 2024 | 3024 | 0.610 |
Why?
|
Cell Line, Tumor | 20 | 2024 | 16945 | 0.560 |
Why?
|
Benzimidazoles | 3 | 2014 | 855 | 0.560 |
Why?
|
Piperazines | 3 | 2024 | 2519 | 0.540 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 570 | 0.540 |
Why?
|
Medulloblastoma | 3 | 2008 | 678 | 0.530 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 733 | 0.520 |
Why?
|
Cholangiocarcinoma | 5 | 2024 | 552 | 0.520 |
Why?
|
Molecular Targeted Therapy | 9 | 2021 | 2805 | 0.500 |
Why?
|
MAP Kinase Kinase Kinases | 2 | 2014 | 255 | 0.400 |
Why?
|
Oximes | 3 | 2020 | 303 | 0.400 |
Why?
|
Melanoma | 3 | 2023 | 5704 | 0.390 |
Why?
|
GTP Phosphohydrolases | 3 | 2024 | 516 | 0.390 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2021 | 1725 | 0.380 |
Why?
|
Rectal Neoplasms | 4 | 2021 | 1157 | 0.380 |
Why?
|
Imidazoles | 4 | 2020 | 1179 | 0.380 |
Why?
|
Membrane Proteins | 4 | 2024 | 7849 | 0.380 |
Why?
|
Bile Duct Neoplasms | 3 | 2024 | 605 | 0.370 |
Why?
|
Pancreatic Neoplasms | 7 | 2021 | 5359 | 0.360 |
Why?
|
Cerebellar Neoplasms | 2 | 2008 | 586 | 0.350 |
Why?
|
Humans | 90 | 2024 | 760437 | 0.350 |
Why?
|
Multiprotein Complexes | 2 | 2013 | 1119 | 0.350 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2024 | 3590 | 0.340 |
Why?
|
Stomach Neoplasms | 2 | 2020 | 1428 | 0.340 |
Why?
|
Esophageal Neoplasms | 2 | 2020 | 1646 | 0.330 |
Why?
|
Genes, ras | 1 | 2011 | 653 | 0.310 |
Why?
|
Oncogene Protein p21(ras) | 2 | 2019 | 68 | 0.290 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2013 | 2058 | 0.290 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3631 | 0.290 |
Why?
|
Signal Transduction | 12 | 2024 | 23397 | 0.290 |
Why?
|
Feedback | 2 | 2022 | 791 | 0.280 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2008 | 269 | 0.280 |
Why?
|
Indoles | 2 | 2013 | 1833 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5296 | 0.280 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 870 | 0.280 |
Why?
|
Sterols | 1 | 2006 | 63 | 0.270 |
Why?
|
Neoplasm Metastasis | 5 | 2024 | 4903 | 0.230 |
Why?
|
Precancerous Conditions | 1 | 2011 | 978 | 0.230 |
Why?
|
Immunoconjugates | 2 | 2023 | 953 | 0.230 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2024 | 2860 | 0.220 |
Why?
|
Mice, Nude | 6 | 2018 | 3603 | 0.210 |
Why?
|
Mice | 20 | 2024 | 81402 | 0.210 |
Why?
|
Receptors, Cell Surface | 3 | 2009 | 2819 | 0.200 |
Why?
|
Animals | 27 | 2024 | 168253 | 0.190 |
Why?
|
Heterozygote | 1 | 2008 | 2798 | 0.190 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2011 | 2821 | 0.190 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 225 | 0.190 |
Why?
|
Microsatellite Repeats | 2 | 2021 | 785 | 0.190 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2001 | 38 | 0.190 |
Why?
|
Lung Neoplasms | 4 | 2021 | 13312 | 0.180 |
Why?
|
Neoadjuvant Therapy | 3 | 2021 | 2821 | 0.180 |
Why?
|
DNA Mismatch Repair | 2 | 2021 | 428 | 0.180 |
Why?
|
Survival Rate | 5 | 2020 | 12698 | 0.170 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.170 |
Why?
|
Prognosis | 9 | 2024 | 29551 | 0.170 |
Why?
|
Treatment Outcome | 11 | 2024 | 64591 | 0.170 |
Why?
|
Papillomavirus Infections | 2 | 2022 | 1610 | 0.170 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2020 | 2509 | 0.170 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4319 | 0.170 |
Why?
|
Immune Evasion | 1 | 2023 | 363 | 0.160 |
Why?
|
Female | 35 | 2024 | 391875 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 218 | 0.160 |
Why?
|
RNA Editing | 1 | 2020 | 151 | 0.160 |
Why?
|
Retinoblastoma Protein | 1 | 2022 | 671 | 0.160 |
Why?
|
Oncogenes | 3 | 2019 | 1223 | 0.160 |
Why?
|
Trans-Activators | 2 | 2006 | 2858 | 0.160 |
Why?
|
Cytidine Deaminase | 1 | 2020 | 245 | 0.150 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58859 | 0.150 |
Why?
|
Phosphorylation | 4 | 2016 | 8311 | 0.150 |
Why?
|
Middle Aged | 24 | 2024 | 220382 | 0.150 |
Why?
|
Tolmetin | 1 | 1997 | 24 | 0.150 |
Why?
|
Transcriptional Activation | 3 | 2015 | 1753 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 265 | 0.150 |
Why?
|
Head and Neck Neoplasms | 2 | 2022 | 2891 | 0.140 |
Why?
|
Immunotherapy | 3 | 2023 | 4649 | 0.140 |
Why?
|
Aged | 20 | 2024 | 168840 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2022 | 1246 | 0.140 |
Why?
|
Phenylurea Compounds | 2 | 2019 | 528 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 8519 | 0.140 |
Why?
|
Medical Oncology | 2 | 2020 | 2318 | 0.140 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2016 | 716 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2019 | 479 | 0.140 |
Why?
|
Male | 28 | 2024 | 360035 | 0.140 |
Why?
|
Proto-Oncogene Proteins | 6 | 2015 | 4509 | 0.140 |
Why?
|
Japan | 1 | 2020 | 1366 | 0.130 |
Why?
|
Biopsy | 2 | 2020 | 6765 | 0.130 |
Why?
|
Pain, Intractable | 1 | 1997 | 132 | 0.130 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2022 | 491 | 0.130 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2020 | 825 | 0.130 |
Why?
|
Autopsy | 1 | 2019 | 1005 | 0.130 |
Why?
|
Mutation, Missense | 2 | 2018 | 2571 | 0.130 |
Why?
|
Cytomegalovirus | 1 | 2020 | 755 | 0.120 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6330 | 0.120 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 256 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9267 | 0.120 |
Why?
|
Standard of Care | 1 | 2018 | 550 | 0.120 |
Why?
|
Canada | 1 | 2020 | 2119 | 0.120 |
Why?
|
Pyridazines | 1 | 2016 | 201 | 0.120 |
Why?
|
Oxygen | 1 | 2006 | 4222 | 0.120 |
Why?
|
Antibodies | 2 | 2020 | 2421 | 0.110 |
Why?
|
Analgesics, Non-Narcotic | 1 | 1997 | 370 | 0.110 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2553 | 0.110 |
Why?
|
Morpholines | 2 | 2014 | 580 | 0.110 |
Why?
|
Ribosomal Protein S6 | 1 | 2013 | 71 | 0.110 |
Why?
|
Mutant Proteins | 2 | 2016 | 491 | 0.110 |
Why?
|
Colonic Neoplasms | 2 | 2023 | 2529 | 0.110 |
Why?
|
Exons | 1 | 2019 | 2392 | 0.110 |
Why?
|
Autocrine Communication | 1 | 2014 | 169 | 0.110 |
Why?
|
Hedgehog Proteins | 2 | 2009 | 768 | 0.110 |
Why?
|
Adenosine Triphosphate | 1 | 2019 | 1989 | 0.100 |
Why?
|
Leucovorin | 3 | 2021 | 642 | 0.100 |
Why?
|
Carcinoma | 1 | 2023 | 2328 | 0.100 |
Why?
|
Adult | 16 | 2024 | 220781 | 0.100 |
Why?
|
Blotting, Western | 2 | 2010 | 5031 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 940 | 0.100 |
Why?
|
Genomics | 2 | 2018 | 5806 | 0.100 |
Why?
|
Antigen Presentation | 1 | 2017 | 1254 | 0.100 |
Why?
|
Microsatellite Instability | 1 | 2015 | 715 | 0.100 |
Why?
|
Gene Dosage | 1 | 2016 | 1218 | 0.100 |
Why?
|
HT29 Cells | 1 | 2012 | 192 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2024 | 2204 | 0.100 |
Why?
|
Mice, SCID | 2 | 2019 | 2625 | 0.090 |
Why?
|
Antibodies, Monoclonal | 3 | 2017 | 9176 | 0.090 |
Why?
|
Cohort Studies | 6 | 2023 | 41366 | 0.090 |
Why?
|
Cell Growth Processes | 1 | 2012 | 384 | 0.090 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 614 | 0.090 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2024 | 105 | 0.090 |
Why?
|
Chromatin | 1 | 2022 | 2951 | 0.090 |
Why?
|
Influenza Vaccines | 1 | 1997 | 763 | 0.090 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2009 | 1248 | 0.090 |
Why?
|
Inhibitory Concentration 50 | 1 | 2010 | 465 | 0.090 |
Why?
|
DNA Primers | 2 | 2011 | 2820 | 0.080 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1114 | 0.080 |
Why?
|
Fluorouracil | 3 | 2021 | 1637 | 0.080 |
Why?
|
Weight Loss | 1 | 2021 | 2683 | 0.080 |
Why?
|
Prospective Studies | 5 | 2021 | 54339 | 0.080 |
Why?
|
Proteins | 2 | 2023 | 6033 | 0.080 |
Why?
|
DNA Damage | 1 | 2019 | 2441 | 0.080 |
Why?
|
Cell Proliferation | 4 | 2024 | 10425 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11096 | 0.080 |
Why?
|
Benzamides | 1 | 2014 | 1370 | 0.080 |
Why?
|
Quality of Life | 3 | 2023 | 13338 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4879 | 0.070 |
Why?
|
Influenza, Human | 1 | 1997 | 1517 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4575 | 0.070 |
Why?
|
Down-Regulation | 1 | 2013 | 2911 | 0.070 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2011 | 1135 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13484 | 0.060 |
Why?
|
Transcription, Genetic | 3 | 2021 | 7597 | 0.060 |
Why?
|
Papillomaviridae | 2 | 2022 | 1119 | 0.060 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9410 | 0.060 |
Why?
|
Vaccination | 1 | 1997 | 3375 | 0.060 |
Why?
|
RNA, Small Interfering | 2 | 2011 | 3428 | 0.060 |
Why?
|
Treatment Failure | 1 | 2011 | 2642 | 0.060 |
Why?
|
Ireland | 3 | 2002 | 171 | 0.060 |
Why?
|
In Situ Hybridization | 1 | 2008 | 1900 | 0.060 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2024 | 897 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1624 | 0.060 |
Why?
|
DNA Methylation | 1 | 2018 | 4383 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3183 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14565 | 0.050 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11070 | 0.050 |
Why?
|
Cell Line | 4 | 2020 | 15598 | 0.050 |
Why?
|
Tumor Necrosis Factors | 1 | 2023 | 107 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6570 | 0.050 |
Why?
|
Neoplasms, Experimental | 3 | 2017 | 1228 | 0.050 |
Why?
|
Pediatrics | 1 | 2018 | 3593 | 0.050 |
Why?
|
Mice, Transgenic | 2 | 2014 | 9533 | 0.050 |
Why?
|
Apoptosis | 3 | 2013 | 9468 | 0.050 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2024 | 296 | 0.050 |
Why?
|
Carcinoembryonic Antigen | 1 | 2023 | 337 | 0.050 |
Why?
|
E2F1 Transcription Factor | 1 | 2022 | 178 | 0.050 |
Why?
|
STAT Transcription Factors | 1 | 2023 | 188 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2010 | 6230 | 0.050 |
Why?
|
E2F Transcription Factors | 1 | 2022 | 269 | 0.050 |
Why?
|
Molecular Structure | 1 | 2006 | 1875 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2019 | 6128 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 330 | 0.050 |
Why?
|
Janus Kinases | 1 | 2023 | 249 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 160 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4567 | 0.050 |
Why?
|
Spheroids, Cellular | 1 | 2023 | 329 | 0.050 |
Why?
|
Transcription Factor AP-1 | 1 | 2022 | 321 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2021 | 384 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 365 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2911 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3777 | 0.040 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2002 | 394 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 876 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4735 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20551 | 0.040 |
Why?
|
Enzyme Assays | 1 | 2020 | 104 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6475 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2020 | 295 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 704 | 0.040 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3446 | 0.040 |
Why?
|
Esophagogastric Junction | 1 | 2020 | 343 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12653 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39078 | 0.040 |
Why?
|
Growth Substances | 1 | 2000 | 768 | 0.040 |
Why?
|
Matrix Metalloproteinases | 1 | 2020 | 392 | 0.040 |
Why?
|
Transcription Factor TFIIIA | 1 | 2016 | 24 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2018 | 9003 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 960 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2017 | 329 | 0.030 |
Why?
|
Ketorolac | 1 | 1997 | 94 | 0.030 |
Why?
|
Young Adult | 2 | 2021 | 59068 | 0.030 |
Why?
|
Organoids | 1 | 2023 | 741 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2021 | 823 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 20985 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 841 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 547 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2000 | 718 | 0.030 |
Why?
|
Stromal Cells | 1 | 2021 | 1330 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 1997 | 678 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 782 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 997 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2017 | 659 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1824 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 7996 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2201 | 0.030 |
Why?
|
Radiotherapy | 1 | 2021 | 1498 | 0.030 |
Why?
|
Family Practice | 1 | 1997 | 509 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9462 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2023 | 3157 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2000 | 1341 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6377 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18216 | 0.030 |
Why?
|
Gene Fusion | 1 | 2016 | 354 | 0.030 |
Why?
|
Outpatients | 1 | 2002 | 1596 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 281 | 0.030 |
Why?
|
Feedback, Physiological | 1 | 2016 | 476 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5778 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3075 | 0.030 |
Why?
|
Zebrafish Proteins | 1 | 2000 | 1012 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2020 | 1355 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2021 | 80430 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2015 | 407 | 0.030 |
Why?
|
Chemokine CCL5 | 1 | 2014 | 215 | 0.030 |
Why?
|
I-kappa B Proteins | 1 | 2014 | 211 | 0.030 |
Why?
|
Codon | 1 | 2015 | 602 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1588 | 0.030 |
Why?
|
Point Mutation | 1 | 2017 | 1595 | 0.030 |
Why?
|
Patient Satisfaction | 2 | 2002 | 3457 | 0.030 |
Why?
|
Colon | 1 | 2020 | 1791 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2721 | 0.030 |
Why?
|
Monocytes | 1 | 2021 | 2572 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2002 | 1792 | 0.020 |
Why?
|
Confidence Intervals | 1 | 1997 | 2927 | 0.020 |
Why?
|
Clone Cells | 1 | 2015 | 1660 | 0.020 |
Why?
|
RNA Interference | 1 | 2020 | 2832 | 0.020 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 88 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1994 | 0.020 |
Why?
|
Camptothecin | 1 | 2015 | 590 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2870 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1035 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2019 | 1605 | 0.020 |
Why?
|
Cell Death | 1 | 2016 | 1664 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4277 | 0.020 |
Why?
|
Aminopyridines | 1 | 2014 | 570 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 6206 | 0.020 |
Why?
|
Drug Synergism | 1 | 2014 | 1755 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1751 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2016 | 3592 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2018 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1463 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1850 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3066 | 0.020 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2000 | 1410 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1739 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17854 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 1997 | 4849 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2020 | 5491 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2044 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3764 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3541 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14397 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2501 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7208 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1371 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8611 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 2014 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8826 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1610 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1404 | 0.020 |
Why?
|
Pain Measurement | 1 | 1997 | 3546 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3874 | 0.020 |
Why?
|
Genetic Testing | 1 | 2019 | 3535 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2021 | 4923 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 6086 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1997 | 10759 | 0.020 |
Why?
|
Child | 3 | 2023 | 80086 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 1997 | 5491 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15257 | 0.010 |
Why?
|
Alleles | 1 | 2015 | 6908 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10188 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2014 | 3209 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2385 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2453 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 21322 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10746 | 0.010 |
Why?
|
Base Sequence | 1 | 2011 | 12449 | 0.010 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2000 | 24 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 1997 | 7380 | 0.010 |
Why?
|
Wnt1 Protein | 1 | 2000 | 120 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22121 | 0.010 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 502 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2000 | 1693 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 88196 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2000 | 718 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2000 | 1494 | 0.010 |
Why?
|
Postoperative Period | 1 | 2000 | 1807 | 0.010 |
Why?
|
beta Catenin | 1 | 2000 | 1040 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2000 | 4174 | 0.010 |
Why?
|
United States | 1 | 2020 | 72202 | 0.010 |
Why?
|
Transfection | 1 | 2000 | 5776 | 0.010 |
Why?
|
Preoperative Care | 1 | 2000 | 2242 | 0.010 |
Why?
|
Binding Sites | 1 | 2000 | 6042 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2000 | 6525 | 0.010 |
Why?
|
Recovery of Function | 1 | 2000 | 2975 | 0.010 |
Why?
|
Fibroblasts | 1 | 2000 | 4106 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2000 | 13445 | 0.000 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 3880 | 0.000 |
Why?
|
Logistic Models | 1 | 2002 | 13240 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 2000 | 17639 | 0.000 |
Why?
|
Kidney | 1 | 2000 | 7046 | 0.000 |
Why?
|
Rats | 1 | 2000 | 23712 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2000 | 11900 | 0.000 |
Why?
|